Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
IsraelRecruitingPHASE1
Conditions
Pancreatic Ductal Adenocarcinoma · Non-small Cell Lung Cancer · HR+/HER2- Ductal and Lobular Breast Cancer · Triple Negative Breast Cancer · Colorectal Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
- Uni of Alabama at Birmingham, Birmingham, Alabama, United States
- University of California LA, Los Angeles, California, United States
- Stanford University Medical Center, Palo Alto, California, United States
- Mayo Clinic Jacksonville, Jacksonville, Florida, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- BAMF Health, Grand Rapids, Michigan, United States
- BAMF Health, Grand Rapids, Michigan, United States
- Mayo Clinic Rochester, Rochester, Minnesota, United States
- Uni Of TX MD Anderson Cancer Cntr, Houston, Texas, United States
- University Of Washington, Seattle, Washington, United States
- Novartis Investigative Site, Brussels, Belgium
- Novartis Investigative Site, Toronto, Ontario, Canada
- Novartis Investigative Site, Toronto, Ontario, Canada
- Novartis Investigative Site, Montreal, Quebec, Canada
- Novartis Investigative Site, Montreal, Quebec, Canada
- Novartis Investigative Site, Bron, France
- Novartis Investigative Site, Villejuif, France
- Novartis Investigative Site, Cologne, North Rhine-Westphalia, Germany
- Novartis Investigative Site, Essen, Germany
- Novartis Investigative Site, München, Germany
- Novartis Investigative Site, Rostock, Germany
- Novartis Investigative Site, Tel Aviv, Israel
- Novartis Investigative Site, Milan, MI, Italy
- Novartis Investigative Site, Reggio Emilia, RE, Italy
- Novartis Investigative Site, Nijmegen, Gelderland, Netherlands
- Novartis Investigative Site, Utrecht, Netherlands
- Novartis Investigative Site, Barcelona, Spain
- Novartis Investigative Site, Madrid, Spain
- Novartis Investigative Site, Madrid, Spain
- Novartis Investigative Site, Geneva, Switzerland
- Novartis Investigative Site, Lausanne, Switzerland